The researchers in this study evaluated the extent to which treatment effect on brain atrophy is able to mediate the effect on disability progression in RRMS at the clinical trial level. They reviewed data from all randomised clinical trials in RRMS lasting at least two years, which included 13 trials and more than 13,500 people with RRMS, to assess the relationship between the treatment effects on MRI markers and on disability progression.
The treatment effects on disability progression were correlated with treatment effects on brain atrophy and on active MRI lesions. After analysis on both MRI endpoints, the treatment effect on brain atrophy is correlated with the effect on disability progression over two years. This is independent of the effect of active MRI lesions on disability. Therefore, the two MRI measures predict the treatment effect on disability more closely when used in combination suggesting a potential role of both MR measures in mediating part of treatment effects detected on clinical disability in MS.
Authors: Sormani MP, Arnold DL
Source: Ann Neurol. 2013 Sep 5. doi: 10.1002/ana.24018. [Epub ahead of print]
Read the abstract